Latest Conference Articles

Experts discuss real-world BTCE challenges, toxicity monitoring, and evolving pharmacy practice.

Practical insights for navigating rare, high-stakes toxicities.

Expert insights on toxicity management, resistance mechanisms, and frontline integration of Bruton tyrosine kinase inhibitors in MCL.

New data, emerging targets, and evolving ADC use are reshaping second-line decisions.

Experts discuss the 340B Pricing Program, sharing updates, ongoing challenges, and solutions for pharmacists.

Matthew Warrick, PharmD, BCPS, BCOP, discusses mechanisms, safety nuances, and practical considerations shaping bispecific antibody use in lymphoma care.

Jacinda “JAM" Abdul-Mutakabbir, PharmD, MPH, discusses the adult burden of respiratory syncytial virus (RSV) and the critical role of pharmacists in vaccine access and education—especially for marginalized populations.

Tarlatamab, a DLL3 T‑cell engager, advances treatment of extensive‑stage SCLC.

Insights from the 2026 HOPA Annual Conference highlight the pharmacist's role in operationalizing belantamab mafodotin.

Oncology pharmacist Emma Jones, PharmD, BCOP, outlines how clinicians can recognize and manage these complex cases.

A dual-center retrospective study compares 2 fludarabine washout strategies to assess their impact on neutrophil engraftment, infections, growth factor use, and hospital length of stay.

Disha Patel, PharmD, discusses current data on G-CSF use during HiDAC consolidation for AML, addressing relapse concerns, infection risk, clinical decision-making, and why practice patterns remain divided across institutions.

Ahead of the Sports Pharmacy Summit, a pharmacist weighs GLP-1s for athlete weight management benefits.

From bispecifics to real-world evidence, Amy Seung previews the science, community, and advocacy opportunities defining this year's meeting.

New AAAAI data spotlight oral remibrutinib for CSU, next-generation peanut allergy therapies, infant microbiome prevention, and GLP‑1 receptor agonists linked to fewer asthma flares.

VOYAGE trial data show dupilumab improves pediatric asthma control and lowers exacerbations versus placebo, with higher remission and lung function gains earlier.

Wildfire smoke exposure increases asthma morbidity, underscoring the pharmacist’s role in medication preparedness and patient education.

Phase 2 trial data support the safety and efficacy of remibrutinib in adults with peanut allergy.

Emerging skin lipid biomarkers precede atopic dermatitis and food allergy, emphasizing barrier restoration as a key therapeutic target for pharmacists.

Remibrutinib is the first oral advanced therapy for adults with chronic spontaneous urticaria (CSU) who remain uncontrolled on high-dose second-generation antihistamines.

Data show the peanut allergy sublingual immunotherapy (SLIT) tablet is well-tolerated across ages, offering promising sublingual immunotherapy desensitization with manageable adverse effects.

AAAAI 2026 highlights STMC-103H live biotherapeutic, showing reduced atopic disease risk in at-risk infants—potentially an early microbiome intervention for atopic dermatitis and food allergy.

Careful history, adherence support, and proper medication technique are central to diagnosing and managing chronic cough in children.

Social determinants of health and environmental exposures during extreme weather events worsen asthma outcomes.

Emerging targets are reshaping how mCRPC is treated, as showcased at the 2026 American Society of Clinical Oncology Genitourinary Cancers Symposium.

Remibrutinib, an oral Bruton tyrosine kinase inhibitor for chronic spontaneous urticaria (CSU), delivers itch and hive relief within 12 hours and sustains improvements through week 1.

Data presented at AAAAI 2026 show tapinarof cream improves sleep for children as young as 2 years with atopic dermatitis, easing nighttime disruption.

Data presented at the 2026 ASCO Genitourinary Cancers Symposium show the benefit of enfortumab vedotin-ejfv plus pembrolizumab in muscle-invasive bladder cancer.